Goldman Sachs no for a longer time expects the Fed to hike premiums in March, cites strain on banking procedure

Goldman Sachs no for a longer time expects the Fed to hike premiums in March, cites strain on banking procedure


Vital Points
  • “In light-weight of the anxiety in the banking process, we no extended hope the FOMC to deliver a rate hike at its next conference on March 22,” Goldman economist Jan Hatzius stated in a Sunday take note.
  • The business expects the newest actions to “deliver significant liquidity to financial institutions facing deposit outflows” and improve self-assurance amid depositors.



Resource

Stocks making the biggest moves midday: Firefly Aerospace, Fortinet, Duolingo, Eli Lilly and more
Finance

Stocks making the biggest moves midday: Firefly Aerospace, Fortinet, Duolingo, Eli Lilly and more

Check out some of the companies making headlines in midday trading: Firefly Aerospace — Shares of the Texas-based rocket maker surged more than 50% as they debuted Thursday afternoon on the Nasdaq under the “FLY” ticker symbol. On Wednesday, the stock priced in its initial public offering at $45 each, which was above its expected […]

Read More
Prediction markets have a new favorite for the next Fed Chair — Christopher Waller
Finance

Prediction markets have a new favorite for the next Fed Chair — Christopher Waller

Federal Reserve Governor Christopher Waller converses on the sidelines of a monetary policy conference at Stanford University’s Hoover Institution in Palo Alto, California, U.S., May 9, 2025. Ann Saphir | Reuters The odds that Federal Reserve Governor Christopher Waller will be named the next chairman crossed above 50% for the first time on prediction market […]

Read More
Stocks making the biggest moves premarket: Eli Lilly, Peloton, Intel, Duolingo and more
Finance

Stocks making the biggest moves premarket: Eli Lilly, Peloton, Intel, Duolingo and more

Check out the companies making headlines before the bell. Eli Lilly — The pharmaceutical stock dropped more than 7% despite posting a second-quarter earnings and revenue beat . The company also raised guidance for both its full-year earnings and revenue. Meantime, Eli Lilly reported that the highest dose of an experimental daily pill helped patients […]

Read More